942 results on '"Herzog, Roland W."'
Search Results
2. SERCA2a overexpression improves muscle function in a canine Duchenne muscular dystrophy model
3. Chemical modification of AAV9 capsid with N-ethyl maleimide alters vector tissue tropism
4. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies
5. B cell focused transient immune suppression protocol for efficient AAV readministration to the liver
6. A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR
7. TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling
8. Cellular stress and coagulation factor production: when more is not necessarily better
9. Factor IX administration in the skin primes inhibitor formation and sensitizes hemophilia B mice to systemic factor IX administration
10. A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?
11. Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells
12. Plant cell-based drug delivery enhances affordability of biologics
13. Assessment of the Gene Therapy Immune Response in the Canine Muscular Dystrophy Model
14. In memoriam: Kenneth I. Berns, MD, PhD (1938–2024)
15. Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma
16. IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice
17. Immune complications and their management in inherited and acquired bleeding disorders
18. Viral Vector Based Immunotherapy for Peanut Allergy.
19. Innate Immune Sensing of Adeno-Associated Virus Vectors.
20. Kenneth I. Berns, MD, PhD [1938–2024]
21. Thorough molecular configuration analysis of noncanonical AAV genomes in AAV vector preparations
22. Expansion, in vivo–ex vivo cycling, and genetic manipulation of primary human hepatocytes
23. Comprehensive Comparison of AAV Purification Methods: Iodixanol Gradient Centrifugation vs. Immuno-Affinity Chromatography
24. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies
25. The Nobel Prize awarded to pioneers of mRNA vaccines
26. Looking to the future of gene therapy for hemophilia A and B
27. Cellular stress and coagulation factor production: when more isn’t necessarily better
28. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models
29. Plant cell-made protein antigens for induction of Oral tolerance
30. SLAMF6 in health and disease: Implications for therapeutic targeting
31. Update on clinical gene therapy for hemophilia
32. Potential role for oral tolerance in gene therapy
33. The Molecular Therapy family of journals continues to lead the field of gene and cell therapy
34. ASGCT 2023—Gene therapy is becoming medicine
35. Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice
36. Distortion of journal impact factors in the era of paper mills
37. Supplementary Tables and Figures from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
38. Data from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
39. Supplementary Legends from SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
40. Innovation and clinical progress in oral tolerance
41. TLR9-independent CD8+T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling
42. Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells
43. The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose
44. Distinct functions and transcriptional signatures in orally induced regulatory T cell populations.
45. AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
46. Suppression of anti-drug antibody formation against coagulation factor VIII by oral delivery of anti-CD3 monoclonal antibody in hemophilia A mice
47. Two gene therapies for hemophilia available: Now what?
48. Adenoviral gene therapy for bladder cancer
49. Stable Gene Transfer and Expression of Human Blood Coagulation Factor IX after Intramuscular Injection of Recombinant Adeno-Associated Virus
50. First hemophilia B gene therapy approved: More than two decades in the making
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.